Barclays initiated coverage of Sutro Biopharma (NasdaqGM: STRO) with an “Overweight” recommendation on May 28, 2026. Analysts project a one-year price target of $33.97 per share, reflecting a potential upside of 14.40% from the latest closing price of $29.69.
The company is expected to report annual revenue of $172 million, marking a 68% increase, with a projected non-GAAP EPS of -2.37. Institutional ownership has surged with 76 funds reporting positions, an increase of 28.81% from the previous quarter, resulting in a total of 14,394,000 shares owned, up 171.14%.
Notable shareholders include BVF with 1,252,000 shares (7.56% ownership), Affinity Asset Advisors (1,070,000 shares, 6.46% ownership), and Samsara BioCapital (1,063,000 shares, 6.42% ownership), all reflecting significant increases in their holdings over the last quarter.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
